News
Almirall joins IL-2 push in autoimmunity with $507m Simcere ...
Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.
